IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
Fred GebhartA special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting. Read more
Study Shows Patients at Lowest Risk May Benefit from Longer Intervals Between Lung Cancer Screening
Fred GebhartDr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes. Read more
Analyzing the CheckMate Trials: How do Clinicians Choose the Winning Strategy for Patients With Resectable NSCLC?
Krithika Subramanian, PhDDuring WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future. Read more
Phase II FLOWERS Trial Unveils Potential New First-Line Therapy Option
Fred GebhartResults from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC. Read more
Analysis of Membrane-Bound TROP2 in TROPION-Lung01 Underscores Seminal Advance in Lung Cancer Digital Pathology
Krithika Subramanian, PhDA novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC. Read more
FURTHER Study Moves the Needle Farther on Targeted Therapy Directed at Atypical EGFR Mutations in NSCLC
Krithika Subramanian, PhDFurmonertinib, an oral, brain-penetrant, mutation-selective EGFR TKI, demonstrates activity in patients with EGFR PACC mutations. Read more
Aumolertinib After CRT Significantly Improves PFS in EGFR-mutated Unresectable NSCLC
Fred GebhartThe third-generation EGFR TKI joins osimertinib in demonstrating a meaningful progression-free survival benefit for consolidation following chemoradiation. Read more
Closing Plenary Will Focus on the Importance of Advancing Patient Advocacy
Fred GebhartExperts will focus on overcoming barriers in patient advocacy on a global basis and enhancing the patient-physician partnership. Read more
IASLC Lectureships Focus on Contributions of Leaders in Thoracic Oncology
Erin JungmeyerTuesday morning, nine expert clinicians and researchers in the field will give award lectures in honor of their contributions to the treatment of lung cancer. Read more
Session to Report Results of IASLC’s First Diversity, Equity, and Inclusion Survey
Fred GebhartDrs. Narjust Florez and Cecilia Pompili will co-chair the session, which will also include tips for improving inclusion in clinical trials, creating a mutually respective work environment, and more. Read more